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Status epilepticus (SE), a medical emergency that is typically ter-
minated through antiepileptic drug treatment, leads to hippocam-
pus dysfunction typified by neurodegeneration, inflammation,
altered neurogenesis, as well as cognitive and memory deficits.
Here, we examined the effects of intranasal (IN) administration of
extracellular vesicles (EVs) secreted from human bone marrow-
derived mesenchymal stem cells (MSCs) on SE-induced adverse
changes. The EVs used in this study are referred to as A1-exosomes
because of their robust antiinflammatory properties. We subjected
young mice to pilocarpine-induced SE for 2 h and then administered
A1-exosomes or vehicle IN twice over 24 h. The A1-exosomes reached
the hippocampus within 6 h of administration, and animals receiving
them exhibited diminished loss of glutamatergic and GABAergic
neurons and greatly reduced inflammation in the hippocampus.
Moreover, the neuroprotective and antiinflammatory effects of A1-
exosomes were coupled with long-term preservation of normal
hippocampal neurogenesis and cognitive and memory function, in
contrast to waned and abnormal neurogenesis, persistent inflam-
mation, and functional deficits in animals receiving vehicle. These
results provide evidence that IN administration of A1-exosomes is
efficient for minimizing the adverse effects of SE in the hippocampus
and preventing SE-induced cognitive and memory impairments.
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Status epilepticus (SE) is a grave medical crisis that requiresswift remedy through all age groups (1, 2). It can produce
substantial neurodegeneration, blood–brain barrier disruption,
and inflammation in the hippocampus if not extinguished quickly
by antiepileptic drug (AED) treatment (3–5). An episode of ex-
tended SE is sufficient to cause chronic hippocampus dysfunction,
exemplified by persistent inflammation with activation of micro-
glia and monocyte infiltration, loss of sizable fractions of several
subclasses of inhibitory interneurons, aberrant and waned neu-
rogenesis, hippocampus-dependent cognitive and memory im-
pairments, and chronic epilepsy (5–12). Numerous situations such
as head trauma, stroke, Alzheimer’s disease, brain tumor, and
encephalitis can engender SE. Although administration of AEDs
leads to termination of SE in most instances, it does not thwart
the evolution of SE into chronic epilepsy (13–16). A multitude of
changes ensue in the hippocampus after an episode of SE, which
evolve over a period of months, years, or even decades, and result
in chronic epilepsy when they have reached certain thresholds
(11, 17, 18). Hence, there is an urgent need to find an adjuvant
therapy with AEDs that not only provides neuroprotection and
suppression of inflammation in the early phase after SE but also
maintains normal neurogenesis, preserves cognitive and memory
function, and thwarts epilepsy development in the chronic phase
after SE. The i.v. administration of bone marrow-derived mono-
nuclear cells (MNCs) or mesenchymal stem cells (MSCs) has
shown potential for modulating SE-induced adverse effects in
the hippocampus and reducing the severity of chronic epilepsy
(19). However, clinical therapies with MNCs or MSCs face
considerable challenges in regard to the variable biological ac-
tivity of different preparations of the cells and the logistics of
delivering the cells to the bedside or emergency room.
A feasible alternative would be the dispensation of prebanked
extracellular vesicles (EVs) generated from MSCs, as human
MSC (hMSC)-derived EVs seemed to have most of the antiin-
flammatory and neuroprotective activity of MSCs (20). More-
over, several studies suggest that therapeutic benefits of MSC
administration are largely explained by paracrine effects medi-
ated by soluble factors or EVs secreted by MSCs (21–24). Fur-
thermore, EVs can cross the blood–brain barrier and deliver
various therapeutic factors to the brain (25, 26). EVs containing
a multitude of mRNAs, miRNAs, and proteins (26, 27) can be
harvested, characterized, and banked from MSCs obtained from
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several sources such as bone marrow, lipoaspirate of liposuction
procedures, umbilical cord, and human-induced pluripotent stem
cells (28–30). The use of EVs also avoids several potential safety
hazards such as the risk of tumors. Besides, EVs have several
distinct advantages over cells for use in clinical therapies. Their
compositions can be defined and standardized because they are
stable and not responsive to external stimuli. EVs can be made
readily available for use in patients, as they are far more stable to
freezing and thawing. Also, if the small size of EVs makes it
possible to administer them via an IN route, they may be broadly
applicable as a noninvasive therapy.
Therefore, we rigorously ascertained the efficacy of IN ad-
ministration of EVs derived from human bone marrow-derived
MSCs by using a pilocarpine model of SE in mice. The EVs used
in this study have been well characterized and are referred to
as A1-exosomes because of their robust antiinflammatory prop-
erties (20). First, we measured the ability of IN administered
A1-exosomes to enter the hippocampus, suppress inflamma-
tion, and protect glutamatergic and GABAergic neurons in
the early phase after SE. Next, we measured the proficiency of
IN-administered A1-exosomes for maintaining normal neuro-
genesis and cognitive and memory function with persistent sup-
pression of inflammation in the chronic phase after SE.
Results
Preparation, Selection and Characterization of A1-Exosomes from
Human Bone Marrow-Derived MSCs. The generation, isolation,
and capture of EVs of uniform size (80–100 nm in diameter)
from human bone marrow-derived MSCs were performed as
detailed in our recent report (20). The EVs generated through
this procedure were positive for classical EV markers such as
CD63 and CD81 but negative for CD9 and 13 other epitopes
found on the surface of MSCs. Each batch of EVs was also tested
for antiinflammatory activity in the spleen by using a model of
systemic inflammation induced by administration of LPS. Only
EVs that exhibited antiinflammatory activity in the spleen were
labeled as A1-exosomes and used in the SE model. Further de-
tails are provided in SI Materials and Methods.
IN-Dispensed A1-Exosomes Incorporated into Cortical and Hippocampal
Neurons.We investigated whether IN administration of A1-exosomes
after SE would result in targeting of these exosomes into the
hippocampus, the region exhibiting intense hyperactivity of
neurons, increased oxidative stress, and inflammation with in-
filtration of peripheral monocytes during and/or after SE
(5, 12). We administered PKH26-labeled A1-exosomes via IN
route (15 μg, ∼7.5 × 109) immediately after the termination of
2 h of SE by an injection of diazepam. Six hours later, animals
were perfused (n = 4), and serial sections through the entire
brain were processed for immunofluorescence by using mar-
kers of neurons (neuronal nuclear antigen [NeuN]), astrocytes
(GFAP), and microglia (IBA-1) and Z-sectioning in a confocal
microscope. We found red-colored PKH26+ particles (i.e.,
A1-exosomes) throughout the olfactory bulb, frontoparietal cor-
tex, basal forebrain, striatum, and dorsal hippocampus. At dorsal
hippocampal levels, most exosomes were in small clusters and
were seen within the cytoplasm of neurons or attached to the cell
membrane of neurons (Fig. 1 A1–C2). In the hippocampus,
exosomes were clearly seen within dentate hilar neurons (Fig. 1
B1 and B2) and the CA3 pyramidal neurons (Fig. 1 C1 and C2).
Occasionally, exosomes were also found in the cytoplasm of
dentate granule cells (Fig. 1 B1 and B2) and the CA1 pyramidal
neurons. We also examined their presence within GFAP+ as-
trocytes (Fig. 1D) and IBA-1+ microglial cells (Fig. 1E) in the
hippocampus. None were seen in the cell body of astrocytes but
were found inside the cell body of some microglia. However,
exosomes were frequently seen in close proximity to astrocyte
and microglial processes. In rostral regions of the cerebral cor-
tex, accumulation of exosomes could be seen in virtually all
neurons and a vast majority of microglia (Figs. S1 and S2).
Exosomes were also seen in close proximity to processes of as-
trocytes and microglia. Interestingly, whereas neurons displayed
isolated or smaller clusters of exosomes, a greater fraction of
microglia displayed larger clusters of exosomes within their cyto-
plasm (Fig. S2). Thus, within 6 h of IN administration, A1-exosomes
incorporated robustly into neurons and microglia in rostral regions
of the cerebral cortex, and predominantly into neurons in the cortex
and the hippocampus at dorsal hippocampal levels.
IN Delivery of A1-Exosomes After SE Prevented the Rise of Multiple
Proinflammatory Cytokines and Increased the Concentration of Some
Antiinflammatory Cytokines and Growth Factors in the Hippocampus.
We measured 24 cytokines in hippocampal lysates obtained from
animals belonging to different groups (n = 6 per group) at 24 h
post-SE by using 96-well array plates that were precoated with
specific cytokine capture antibodies. Sixteen proinflammatory
cytokines exhibited up-regulation in animals receiving vehicle
after SE (SE-VEH group) in comparison with naive control
animals (Table S1). Among these, the concentrations of seven
proinflammatory cytokines was significantly reduced in animals
receiving A1-exosomes after SE (SE-EVs group; Fig. 2 A–G) in
comparison with animals in the SE-VEH group. These include
TNF-α, IL-1β, monocyte chemoattractant protein-1 (MCP-1),
stem cell factor (SCF), macrophage inflammatory protein-1α
(MIP-1α), GM-CSF, and IL-12. Animals in the SE-EVs group
also displayed enhanced concentrations of antiinflammatory cy-
tokine IL-10 (Fig. 2H), granulocyte colony-stimulating factor
(G-CSF; Fig. 2I), platelet-derived growth factor-β (PDGF-β, Fig.
2J), IL-6 (Fig. 2K), and IL-2 (Fig. 2L). As TNF-α and IL-1β are
among the major proinflammatory cytokines that are implicated
in brain diseases exhibiting inflammation and/or cognitive and
Fig. 1. A1-exosomes invade the frontoparietal cerebral cortex and the
dorsal hippocampus within 6 h after IN administration. (A1–C2) The presence
of PKH26+ exosomes (red dots) within the cytoplasm or in close contact with
the cell membrane of NeuN+ neurons in the cerebral cortex (A1), the DH and
GCL (B1), and CA3 pyramidal neurons (C1) of the hippocampus at 6 h after
their IN administration. (A2, B2, and C2) Magnified views of boxed regions in
A1, B1, and C1. (D) Lack of exosomes within the soma of GFAP+ astrocytes and
the presence of some exosomes adjacent to astrocyte processes. (E) Presence of
exosomes within the soma or processes of some IBA-1+ microglia. CA3-SP,
CA3 stratum pyramidale; CA3-SR, CA3 stratum radiatum; CTX, cortex. (Scale
bars: A1, B1, and C1, 50 μm; A2, B2, and C2, 25 μm; D and E, 25 μm.)
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memory dysfunction and have proconvulsive properties (31), we
further confirmed their concentration through independent
quantitative ELISAs. The results clearly showed their up-
regulation at 24 h post-SE in animals in the SE-VEH group
and normalized levels in the SE-EVs group (Fig. 2 M and N).
Thus, IN administration of A1-exosomes commencing 2 h post-
SE was adequate for greatly easing the inflammatory storm
triggered by SE.
IN Delivery of A1-Exosomes After SE Greatly Reduced the Activation
of Microglia in the Hippocampus. We measured the extent of in-
flammation in the hippocampus at 4 d post-SE in animals re-
ceiving vehicle or A1-exosomes through immunohistochemical
staining of serial sections for ED-1 (CD68, a marker of activated
microglia or macrophages in the brain) and stereological quan-
tification of ED-1+ cells in the dentate gyrus (DG) and CA1 and
CA3 subfields of the hippocampus (n = 5–6 per group; Fig. 3 A1–
E). Animals in the SE-VEH group exhibited increased density of
ED-1+ microglia, with several morphological changes, particu-
larly in the CA1 and CA3 subfields. A fraction of microglia
exhibited hypertrophy of soma with multiple short processes
whereas some others exhibited round or oval-shaped soma with
no or minimal processes, both of which are characteristics of
activated microglia (Fig. 3 A2 and A3). In contrast, animals in
the SE-EVs group exhibited not only reduced density of ED-1+
microglia but also a greatly diminished intensity of ED-1 staining
(Fig. 3 B1–B3). Stereological quantification confirmed reduced
numbers of ED-1+ microglia in the DG (Fig. 3C), CA1 and
CA3 subfields (Fig. 3D), and in the entire hippocampus (Fig.
3E). The reductions were 50% for the DG, 72% for the CA1 and
CA3 subfields, and 66% for the entire hippocampus (P < 0.05–
0.01; Fig. 3 C–E).
IN Delivery of A1-Exosomes After SE Reduced the Overall Loss
of Neurons in the Dentate Hilus and the CA1 Cell Layer of the
Hippocampus. SE typically causes degeneration of neurons in
certain regions/layers of the hippocampus. To ascertain the ex-
tent of SE-induced neurodegeneration in the hippocampus of
animals receiving vehicle or A1-exosomes after SE, we per-
formed NeuN immunostaining of serial sections through the
entire hippocampus at 4 d post-SE (Fig. 4 A1–C3). In compari-
son with naive control animals, the SE-VEH and SE-EVs groups
showed reduced densities of neurons in the dentate hilus (DH)
and the CA1 pyramidal cell layer but no discernable changes in
the granule cell layer (GCL) and the CA3 pyramidal cell layer
(n = 5–6 per group; Fig. 4 A1–C3). Stereological quantification
revealed that the overall neuron loss in the DH and CA1 cell
layer ranged from 40% to 47% in the SE-VEH group (P < 0.001)
and from 25% to 26% in the SE-EVs group (P < 0.01–0.001).
Because of neuroprotection mediated by A1-exosomes, animals
in the SE-EVs group displayed a 30–41% greater number of
neurons than animals in the SE-VEH group (P < 0.01–0.001;
Fig. 4 D and E). Thus, IN administration of A1-exosomes after
Fig. 2. IN administration of A1-exosomes 2 h after
SE eases inflammation in the hippocampus when
examined 24 h post-SE. Bar charts compare the rel-
ative concentrations of multiple cytokines between
naive control animals, SE+VEH animals, and SE+EVs
animals. Assays were by multiplexed ELISAs. Animals
in the SE+VEH group display increased concentration
of proinflammatory cytokines TNF-α, IL-1β, MCP-1,
SCF, MIP-1α, GM-CSF, and IL-12 (A–G), whereas ani-
mals in the SE+EVs group exhibit significantly reduced
concentrations of these cytokines. This group also
showed increased concentration of antiinflammatory
cytokines and growth factors such as IL-10, G-CSF,
PDGF-β, IL-6, and IL-2 (H–L). Bar charts in M and N
compare levels of TNF-α and IL-1β in the hippocampus
measured through independent ELISAs. In compari-
son with naive controls, the concentrations of these
proinflammatory cytokines are increased in the SE+VEH
group but normalized in the SE+EVs group (*P <
0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001).
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SE reduced the loss of neurons in regions of the hippocampus
that are highly susceptible to SE-induced neurodegeneration.
IN Delivery of A1-Exosomes After SE Restrained the Loss of Several
Subclasses of Inhibitory Interneurons in the Hippocampus. Several
subclasses of inhibitory GABAergic interneurons in the hippo-
campus are highly susceptible to SE. To measure the extent of
SE-induced loss of inhibitory interneurons in animals receiving
vehicle or A1-exosomes after SE, we performed immunostaining
of serial sections through the entire hippocampus for the calcium
binding protein parvalbumin (PV), and neuropeptides somato-
statin (SS) and neuropeptide Y (NPY) at 4 d post-SE (n =
5–6 per group). The interneurons positive for PV displayed re-
duced density in the DH-GCL region and the CA1 subfield after
SE (Fig. 4 F1–H3). Stereological measurement demonstrated
that the overall PV+ interneuron loss in the DH-GCL and the
CA1 subfield varied from 43% to 56% in the SE-VEH group
(P < 0.001) and from 24% to 25% in the SE-EVs group (P <
0.01–0.001). Because of the protection mediated by A1-exosomes,
the SE-EVs group displayed 34–69% greater numbers of PV+
interneurons than the SE-VEH group (P < 0.05; Fig. 4 I and J).
Interneurons expressing SS exhibited reduced densities in the
DH+GCL, CA1, and CA3 regions after SE (Fig. 5 A1–C3).
Stereological cell counting showed that the overall SS+ inter-
neuron loss in these regions ranged from 39% to 44% in the SE-
VEH group (P < 0.01–0.001). In contrast, the SE-EVs group
displayed no significant loss in the DH+GCL region and the
CA1 subfield (P > 0.05) but a 27% loss in the CA3 subfield (P <
0.05). In comparison with the SE-VEH group, the SE-EVs group
displayed 47–52% greater numbers of SS+ interneurons in the
DH+GCL and CA1 regions (P < 0.01; Fig. 5 D and E) and a
20% higher number in the CA3 subfield (P > 0.05; Fig. 5F). The
interneurons positive for NPY displayed reduced density only in
the DH-GCL region after SE (Fig. 5 G1–I3). Stereological
quantification revealed that the NPY+ interneuron loss in the
DH+GCL region is 46% in the SE-VEH group and 35% in the
SE-EVs group (P < 0.01; Fig. 5J). In comparison with the SE-
VEH group, the SE-EVs group displayed 22% higher numbers
of NPY+ interneurons (P > 0.05; Fig. 5J). Thus, IN administra-
tion of A1-exosomes after SE diminished the loss of several
subclasses of GABAergic interneurons in the hippocampus.
IN Delivery of A1-Exosomes After SE Averted Cognitive and Memory
Impairments in the Chronic Phase. Cognitive and memory impair-
ments typically ensue after SE. We examined animals 5–6 wk
after SE with vehicle or A1-exosome treatment via three dis-
tinct behavioral tests. These include an object location test
(OLT), a novel object recognition test (NORT), and a pattern
separation test (PST; n = 8–10 per group). We first measured
the cognitive ability of animals through an OLT. The choice to
explore an object displaced to a novel location in this test re-
flects the ability of the animal to discern minor changes in its
immediate environment (Fig. 6A1). Maintenance of this func-
tion depends on the integrity of the hippocampus circuitry (32).
Animals in the SE-VEH group were impaired, as they did not
show affinity for the object moved to a novel place (Fig. 6A3).
Rather, they spent nearly equal amounts of time with the object
in the familiar place and the object in the novel place (P >
0.05). In contrast, animals belonging to the SE-EVs group
showed a greater affinity for exploring the novel place object
(NPO) over the familiar place object (FPO; P < 0.01; Fig. 6A4),
which matched the normal behavior typically observed in naive
control animals (P < 0.0001; Fig. 6A2). As animals belonging
to different groups explored objects for comparable durations (P >
0.05; Fig. 6A5) in the testing phase, the results were not influenced
by variable object exploration times between groups. Thus, SE
causes hippocampus-dependent cognitive dysfunction, but early
intervention with A1-exosomes prevents this impairment.
We next examined recognition memory function by using a
NORT. Recognition memory function depends on the integrity
of the perirhinal cortex and the hippocampus. We examined
animals with a 15-min delay between the “object exploration
phase” comprising the exploration of two identical objects for
5 min in an arena and the “testing phase” involving the ex-
ploration of objects in the same arena but with replacement of
one of the objects with a new object (Fig. 6B1) (32). Animals
belonging to the SE-VEH group showed an inability of novel
object (NO) discrimination, as they spent similar percentages
of time exploring the familiar object (FO) and the NO (P >
0.05; Fig. 6B3). However, animals in the SE-EVs group spent
greater percentages of their object exploration time with the
NO (P < 0.0001; Fig. 6B4), akin to that observed in naive
control animals (P < 0.0001; Fig. 6B2). Again, animals in all
groups explored objects for comparable durations (P > 0.05;
Fig. 3. IN administration of A1-exosomes 2 h after SE greatly reduces the
density of ED-1+ (CD68+) activated microglia in the hippocampus when ex-
amined 4 d post-SE. (A1–B3) Distribution of ED-1+ activated microglia in the
DG (A1 and B1), the CA1 subfield (A2 and B2), and the CA3 subfield (A3 and
B3) of an animal in the SE-VEH group (A1–A3) and an animal in the SE-EVs
group (B1–B3). ML, molecular layer; SO, stratum oriens; SP, stratum pyr-
amidale; SR, stratum radiatum. Bar charts in C–E compare the numbers of
ED-1+ microglia in the DG (C), CA1 and CA3 subfields (D), and the entire
hippocampus (E). Note that animals receiving A1-exosomes (i.e., SE-EVs
group) display reduced numbers of ED-1+ activated microglia compared
with animals in the SE-VEH group (*P < 0.05 and **P < 0.01). (Scale bar:
100 μm.)
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Fig. 6B5) in the testing phase. These results demonstrated that
A1-exosome treatment after SE prevents recognition memory
impairment.
Following the aforementioned cognitive and memory tests, we
further investigated the ability of animals for pattern separation
by using an PST, a relatively complex test for discriminating
analogous experiences through storage of similar representations
in a nonoverlapping manner (33, 34). In this test, each animal
successively explored two different sets of identical objects (ob-
ject types 1 and 2) placed on distinct types of floor patterns
(patterns 1 and 2 [P1 and P2]) for 5 min each in the two ac-
quisition trials separated by 15 min (Fig. 6C1). Fifteen minutes
later, in the testing phase (trial 3), each animal explored an
object from trial 2 (which is now an FO) and an object from trial
1 (which is now an NO) placed on the floor pattern used in trial 2
(i.e., P2). Excellent pattern separation ability in naive animals
was revealed by a greater exploration of the object from trial 1
(i.e., NO on P2) than the object from trial 2 (i.e., FO on P2; P <
0.0001; Fig. 6C2). In contrast, animals belonging to the SE-VEH
group showed no preference for the NO on P2, as they spent
nearly similar amounts of time with the NO and the FO on P2
(P > 0.05; Fig. 6C3), implying an impaired ability for pattern
separation. However, animals in the SE-EVs group spent greater
percentages of their object exploration time with the NO (P <
0.0001; Fig. 6C4), like the behavior seen in naive control animals
(P < 0.0001; Fig. 6C2). These findings were not influenced by
variable object exploration times between groups, as animals
belonging to different groups explored objects for comparable
durations (P > 0.05; Fig. 6C5). Thus, A1-exosome treatment
rescues animals from developing SE-induced pattern separation
dysfunction.
IN Delivery of A1-Exosomes After SE Promoted Normal Hippocampal
Neurogenesis in the Chronic Phase. Hippocampal neurogenesis
exhibits a biphasic response to SE, with increased and abnormal
neurogenesis in the early phase and persistently declined neu-
rogenesis in the chronic phase (6, 7). We investigated the effects
of IN administration of A1-exosomes after SE on long-term
neurogenesis in the hippocampus (i.e., 6 wk after SE; n = 6
per group). In comparison with naive controls (Fig. 7 A1 and
A2), animals in SE-VEH group exhibited decreased neuro-
genesis (P < 0.0001; Fig. 7 B1 and B2), whereas animals in the
SE-EVs group (Fig. 7 C1 and C2) displayed a pattern and extent
of neurogenesis that is equivalent to age-matched naive control
animals (P > 0.05) and a greater extent of neurogenesis than
animals in the SE-VEH group (P < 0.01; Fig. 7D). Furthermore,
SE-VEH animals showed significant loss of dentate hilar neu-
rons positive for reelin, a protein important for directing
the migration of newly born neurons in the subgranular zone
(SGZ) to the GCL (P < 0.01; Fig. 7 E–H). Interestingly, reelin+
positive neuron numbers in the SE-EVs group were compara-
ble to those in naive control animals (P > 0.05; Fig. 7 E–H)
and greater than in the SE-VEH group (P < 0.05). To de-
termine the extent of abnormal migration of newly born granule
cells into the DH, we quantified the numbers of neurons posi-
tive for prox-1 (a marker of dentate granule cells) in the DH
Fig. 4. IN administration of A1-exosomes 2 h after
SE reduces the loss of NeuN+ neurons and PV+ in-
terneurons in the DG and the CA1 subfield when
examined 4 d post-SE. (A1–C3) Distribution of NeuN+
neurons in the DG (A1, B1, and C1), the CA1 subfield
(A2, B2, and C2), and the CA3 subfield (A3, B3, and
C3) of a naive control mouse (A1–A3), a mouse in the
SE-VEH group (B1–B3), and a mouse in the SE-EVs
group (C1–C3). Bar charts in D and E compare the
numbers of NeuN+ neurons in the DH (D) and the
CA1 pyramidal cell layer (E) of the hippocampus.
Although both SE groups display reduced numbers
of NeuN+ neurons in comparison with the naive
control group, the SE-EVs group exhibits greater
numbers of surviving neurons than the SE-VEH
group, implying neuroprotection after IN adminis-
tration of A1-exosomes. (F1–H3) Distribution of PV+
interneurons in the DG (F1, G1, and H1), the CA1
subfield (F2, G2, and H2), and the CA3 subfield (F3,
G3, and H3) of a naive control mouse (F1–F3), a
mouse from the SE-VEH group (G1–G3), and a mouse
from the SE-EVs group (H1–H3). Bar charts in I and J
compare the numbers of PV+ interneurons in the
DH+GCL (I) and the CA1 subfield (J) of the hippo-
campus. Although both SE groups display reduced
numbers of PV+ interneurons in the DH+GCL and
CA1 subfield in comparison with the naive control
group, the SE-EVs group exhibits greater numbers of
PV+ interneurons than the SE-VEH group, implying
protection of these interneurons after IN adminis-
tration of A1-exosomes. SO, stratum oriens, SP,
stratum pyramidale; SR, stratum radiatum (*P < 0.05;
**P < 0.01; ***P < 0.001). (Scale bar: 200 μm.)
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(Fig. 7 I–L). This revealed reduced abnormal migration of
newly born granule cells into the DH in animals belonging to
the SE-EVs group compared with the SE-VEH group (P < 0.05;
Fig. 7L). Thus, A1-exosome treatment after SE facilitated
maintenance of normal pattern and extent of neurogenesis with
preservation of reelin+ neurons and minimal aberrant migration
of newly born granule cells.
IN Delivery of A1-Exosomes After SE Led to Reduced Hippocampal
Inflammation in the Chronic Phase. To examine whether A1-exo-
some–mediated suppression of hippocampal inflammation ob-
served in the early phase after SE persists in the chronic phase,
we examined microglia in the hippocampus through IBA-1 immu-
nostaining 6 wk after SE (Fig. 7 M1–Q). Animals in the SE-VEH
group exhibited enhanced density of microglia with hypertro-
phied soma and thick, short processes (Fig. 7 N1–N3). Such
microglia were prominently seen in the DG and the CA1 subfield.
In contrast, animals in the SE-EVs group showed highly ramified
microglia (Fig. 7 O1–O3), akin to those seen in age-matched naive
control animals (Fig. 7M1–M3). Measurement of the area occupied
by IBA-1–reactive elements revealed increased microglial activity in
DG and CA1 regions of animals belonging to the SE-VEH group
compared with the naive control group and the SE-EVs group (P <
0.001; n = 4 per group; Fig. 7 P–Q). Thus, A1-exosome treatment
early after SE restrained hippocampal inflammation for prolonged
periods.
Discussion
The present results demonstrate that IN delivery of A1-
exosomes 2 h after SE onset is efficacious for reducing multi-
ple SE-induced adverse effects in the hippocampus, a region of
the brain vital for learning and memory. The beneficial effects of
A1-exosome treatment in the early phase after SE comprised
(i) suppression of SE-induced surge in multiple proinflammatory
cytokines, (ii) enhanced expression of a few antiinflammatory
cytokines and trophic factors, (iii) diminished activation of
microglia, (iv) reduced loss of dentate hilar neurons (presumably
comprising excitatory and inhibitory hilar neurons), (v) robust
protection of glutamatergic CA1 pyramidal neurons, and (vi) re-
duced loss of several subclasses of GABAergic inhibitory inter-
neurons, including those expressing the calcium binding protein
PV and neuropeptides SS and NPY. The early favorable effects
after SE led to maintenance of a normal pattern and extent of
neurogenesis with minimal loss of reelin+ interneurons, reduced
aberrant migration of newly born granule cells into the DH, and
diminished inflammation in the chronic phase after SE. Moreover,
the extent of neuroprotective and antiinflammatory effects medi-
ated by A1-exosome treatment was sufficient for preserving nor-
mal cognitive and memory function. Importantly, these changes
were preceded by incorporation of IN-administered A1-exosomes
into a large number of neurons in the frontoparietal cortex and the
dorsal hippocampus, and a vast majority of microglia in rostral
regions of the cortex. In addition, exosomes were frequently seen
Fig. 5. IN administration of A1-exosomes 2 h after
SE reduces the loss of SS+ and NPY+ interneurons in
the hippocampus when examined 4 d post-SE. (A1–
C3) Distribution of SS+ interneurons in the DG (A1,
B1, and C1), the CA1 subfield (A2, B2, and C2), and
the CA3 subfield (A3, B3, and C3) of a naive control
mouse (A1–A3), a mouse in the SE-VEH group (B1–
B3), and a mouse in the SE-EVs group (C1–C3). Bar
charts in D–F compare the numbers of SS+ inter-
neurons in the DH+GCL (D) and the CA1 and
CA3 subfields (E and F) of the hippocampus. All re-
gions display a significant loss of SS+ interneurons in
the SE-VEH group, but only the CA3 subfield shows
some loss in the SE-EVs group. Overall, the SE-EVs
group exhibits greater numbers of SS+ interneu-
rons than the SE-VEH group in all regions, implying a
considerable protection after IN administration of
A1-exosomes. (G1–I3) Distribution of NPY+ inter-
neurons in the DG (G1, H1, and I1), the CA1 subfield
(G2, H2, and I2), and the CA3 subfield (G3, H3, and
I3) of a naive control mouse (G1–G3), a mouse from
the SE-VEH group (H1–H3), and a mouse from the SE-
EVs group (I1–I3). Bar chart in J compares the num-
bers of NPY+ interneurons in the DH+GCL (I) of the
hippocampus. Although both SE groups display re-
duced numbers of NPY+ interneurons in the DH+GCL
in comparison with the naive control group, the SE-
EVs group exhibits relatively greater numbers of PV+
interneurons than the SE-VEH group, implying some
protection of these interneurons after IN adminis-
tration of A1-exosomes. SO, stratum oriens, SP, stra-
tum pyramidale; SR, stratum radiatum (*P < 0.05,
**P < 0.01, and ***P < 0.001). (Scale bar: 200 μm.)
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adjacent to processes of astrocytes and microglia throughout the
frontoparietal cortex and the hippocampus. A proinflammatory
cytokine storm and loss of glutamatergic and GABAergic neu-
rons in the early phase after SE and an abnormal and reduced
neurogenesis with persistent inflammation in the chronic phase
after SE are considered as epileptogenic and cognitive and
memory-impairing alterations. Hence, the favorable outcomes me-
diated through IN administration of A1-exosomes have considerable
significance for developing a therapy that eases the advancement of
primary hippocampal injury into a chronic epileptic state.
Protracted and orchestrated hyperactivity of multiple popu-
lations of neurons typically lead to continuous seizures or SE,
which cause excitotoxic neurodegeneration and neuroinflammation
associated with an increase in the concentration of multiple
proinflammatory cytokines and activation of microglia (5, 35,
36). In this study, IN treatment with A1-exosomes 2 h after SE
resulted in their targeting into the hippocampus within 6 h of
administration, which seemed to provide considerable protection
to glutamatergic neurons and GABAergic interneurons in the
hippocampus. The potential of A1-exosomes as a neurotherapeutic
Fig. 6. IN administration of A1-exosomes after SE
prevents cognitive, memory, and pattern-separation
impairments. (A1, B1, and C1) Depiction of various
phases involved in an OLT (A1), a NORT (B1), and a
PST (C1). Bar charts in A2–A4, B2–B4, and C2–C4
compare percentages of time spent with different
objects. Naive control animals showed a greater af-
finity for (i) the NPO over the FPO in an OLT (A2),
(ii) the NO area (NOA) over the FO area (FOA) in a
NORT (B2), and (iii) NO on P2 over the FO on P2 in a PST
(C2), implying normal cognitive, memory, and pattern-
separation function. However, animals in the SE+VEH
group were impaired in all three tests (A3, B3, and C3).
This was evinced by their behavior of spending nearly
equal amounts of the object exploration time with
the FPO and the NPO in OLT (A3), FOA and NOA in
NORT (B3), and FO on P2 and NO on P2 in the PST
(C3). In contrast, animals in the SE-EVs group showed
a greater affinity for exploring the NPO in OLT (A4),
NOA in NORT (B4), and NO on P2 in PST (C4), sug-
gesting a similar cognitive, memory, and pattern-
separation function as naive control animals. Bar
charts in A5, B5, and C5 show that animals in different
groups explored objects for comparable durations
(**P < 0.01 and ****P < 0.0001).
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product was first discovered in a model of traumatic brain injury
(TBI) when a single i.v. administration of A1-exosomes after TBI
considerably suppressed inflammation and improved spatial
learning and pattern separation ability (20). Nonetheless, the
efficacy of these exosomes when dispensed through an IN route
or in an excitotoxic injury model was unknown. In this regard, the
present study provides compelling evidence that IN administra-
tion of A1-exosomes is neuroprotective when application is
commenced 2 h after SE. Measurement of proinflammatory cy-
tokines 24 h post-SE and activation of microglia 4 d post-SE
revealed that IN treatment of A1-exosomes considerably eases
neuroinflammation resulting from SE. This was exemplified by
the reduced concentration of multiple proinflammatory cyto-
kines, enhanced expression of a few antiinflammatory cytokines
and trophic factors, and reduced occurrence of activated
microglia. The proinflammatory cytokines that showed increased
expression with SE and VEH treatment but reduced expression
with SE and A1-exosome treatment comprised (i) TNF-α, a
prominent cytokine secreted by activated macrophages involved
in inflammation and several brain diseases; (ii) IL1-β, another
prominent cytokine secreted by activated macrophages and in-
volved in inflammation; (iii) MCP-1, a chemokine that regulates
Fig. 7. IN administration of A1-exosomes 2 h after SE restrains multiple adverse changes that are typically seen in the chronic phase after SE. In comparison
with naive control animals (A1, A2, E, I, and M1–M3), animals in the SE-VEH group showed waning of hippocampal neurogenesis [doublecortin (DCX)
immunostaining; B1 and B2], loss of reelin+ interneurons in the DG (F), aberrant migration of newly born prox-1+ granule cells into the DH (J), and persistent
hippocampal inflammation (with increased density and hypertrophy of IBA-1+ microglia; N1–N3). In animals in the SE-EVs group, the extent of neurogenesis
(C1 and C2), the survival of reelin+ interneurons (G), and the morphology and density of IBA-1+ microglia (O1–O3) were comparable to those observed in naive
control animals (A1, A2, E, I, andM1–M3). In addition, aberrant migration of newly born cells into the DH was reduced (K) in these animals. ML, molecular layer.
Bar charts compare numbers of DCX+ newly born neurons in the SGZ-GCL (D), reelin+ interneurons in the DH (H), numbers of prox-1+ newly born granule cells in
the DH (L), and IBA-1+ microglia in the DG (P) and the CA1 subfield (Q) between groups. Note that the extent of neurogenesis (D) and numbers of reelin+ in-
terneurons (H) and IBA-1+ structures (P and Q) in SE-EVs group animals were comparable to those seen in naive control animals. In addition, SE-EVs animals
showed reduced numbers of prox-1+ cells in the DH (L), implying a reduced abnormal migration of newly born granule cells with A1-exosome treatment after SE
(*P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001). (Scale bars: A1, B1, and C1, 200 μm; A2, B2, and C2, 50 μm; E–G and I–K, 200 μm; M1–O3, 100 μm.)
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the migration and infiltration of monocytes and macrophages;
(iv) SCF, a cytokine involved in hematopoiesis; (v) MIP-1α,
a protein involved in leukocyte recruitment; and (vi) GM-CSF,
a protein that stimulates stem cells to produce granulocytes.
Among these, TNF-α and IL-1β are also considered as pro-
convulsant cytokines because of their propensity for contributing
to epileptogenesis and chronic epilepsy development after an
initial injury (31).
The antiinflammatory cytokines or factors that showed en-
hanced expression with A1-exosome treatment include (i) IL-10,
a well-known antiinflammatory cytokine; (ii) G-CSF, a factor
that stimulates bone marrow to produce new blood cells;
(iii) PDGF-β, a factor that promotes angiogenesis; (iv) IL-6, a
cytokine that acts as a proinflammatory and antiinflammatory
protein; and (v) IL-2, a cytokine involved in immune tolerance
and immunity. Furthermore, A1-exosome treatment reduced the
overall number of ED1+ activated microglia in the hippocampus
by 66% when examined 4 d post-SE. Additionally, examination
of IBA-1+ microglia at 6 wk post-SE revealed persistent in-
flammation in animals belonging to the SE-VEH group but not
in the SE-EVs group. Greatly reduced inflammation observed
after SE with A1-exosome treatment has implications because
persistent inflammation is one of the key players in the evolution
of neurodegenerative diseases, including temporal-lobe epilepsy
(37). Indeed, enhanced concentrations of proinflammatory cy-
tokines are constantly observed in the epileptic hippocampus
(38), and are derived from activated microglia/macrophages and
reactive astrocytes (38, 39). In this regard, diminished inflam-
mation with normalization of TNF-α and IL-1β concentrations
and reduced numbers of ED1+ activated microglia in the SE-
EVs group imply that A1-exosome treatment is effective for
curbing the SE-induced inflammation cascade. Considering the
robust incorporation of exosomes into microglia in rostral re-
gions of the cortex and association of exosomes with processes of
microglia and astrocytes in the hippocampus, it is plausible that
antiinflammatory effects of IN administered A1-exosomes were
mediated by modulation of microglia and astrocytes directly or
indirectly through the release of antiinflammatory proteins.
The antiinflammatory effects of A1-exosome treatment were
also accompanied by robust neuroprotection, epitomized by di-
minished loss of neurons in the DH and the CA1 pyramidal cell
layer, two regions in the hippocampus that typically display in-
creased vulnerability to SE-induced neuronal death (5, 40, 41).
Moreover, IN administration of A1-exosomes after SE promoted
preservation of subclasses of GABAergic interneurons, particu-
larly those expressing PV and SS. This was evident in the finding
of 34–69% greater numbers of these interneurons in the DG and
CA1 subfield of animals in the SE-EVs group compared with
animals in the SE-VEH group. Interneuron preservation has
great importance because severe loss of PV+ and SS+ interneurons
leads to chronic epilepsy typified by spontaneous recurrent seizures
and cognitive and mood impairments (41–45). Neuroprotective
effects were likely a consequence of robust antiinflammatory ef-
fects of exosomes. Nonetheless, some direct neuroprotective and/
or neuron-reparative effects through the release of neurotrophic
factors cannot be ruled out as exosomes incorporated into many
neurons in the hippocampus and the frontoparietal cortex.
Another important feature of A1-exosome treatment after SE
was its proficiency in maintaining a normal pattern and extent of
neurogenesis for an extended period after SE and in reducing
the size of aberrant neurogenesis. Animals in the SE-VEH group
exhibited clearly reduced neurogenesis in the SGZ-GCL, whereas
animals in the SE-EVs group presented neurogenesis that was
comparable to age-matched naive control animals. Deviant neu-
rogenesis after SE is exemplified by an anomalous migration of
newly born dentate granule cells into the DH (46, 47). In the
present study, such aberrant migration was ostensible in the SE-
VEH group but significantly lowered in the SE-EVs group.
Dampening of SE-induced aberrant neurogenesis through A1-
exosome treatment has implications because deviant neuro-
genesis has been shown to facilitate the expansion of epileptogenic
circuitry between dentate granule cells relocated to the DH and
CA3 pyramidal neurons. It is currently unknown whether these
anomalies by themselves are adequate to induce spontaneous
seizures (48). Nonetheless, their involvement in manifestations
of spontaneous seizures after SE has been well documented (49–
54). We measured reelin+ interneurons in the DH to identify the
mechanism behind A1-exosome–mediated inhibition of aberrant
neurogenesis, as migration of newly born dentate granule cells
from the SGZ to GCL is steered by reelin protein secreted by
reelin+ interneurons in the DH, and considerable loss of these
neurons fosters aberrant displacement of newly born neurons
into the DH (55). Abnormally migrated prox-1+ new granule
cells were accompanied with a sizable loss of reelin+ interneurons
in the DH of animals in the SE-VEH group. In contrast, a di-
minished extent of aberrant neurogenesis was apparent with the
salvation of reelin+ interneurons in the DH of animals in the SE-
EVs group. Thus, A1-exosome treatment after SE eased aberrant
neurogenesis via protection of reelin+ interneurons, which is likely
a result of repression of inflammation facilitated by A1-exosomes.
Decreased inflammation and normal levels of neurogenesis likely
also contributed to the preservation of cognitive and memory
function in the SE-EVs group, as inflammation and decreased
neurogenesis can impair cognitive and memory function (56, 57). A
series of object-based tests in the present study demonstrated the
impaired ability of animals in the SE-VEH group for cognition and
memory. These include inability to discern minor changes in their
environment in an OLT, identifying an NO in an NORT, and
pattern separation in a PST. However, animals in the SE-EVs group
exhibited similar ability as age-matched naive control animals in
these tests, underscoring that A1-exosome treatment shortly after
SE is efficacious for preventing cognitive and memory impairments.
In summary, the results of the present study establish that IN
A1-exosome treatment after the termination of 2 h of SE can
considerably repress neurodegeneration, neuroinflammation,
aberrant neurogenesis, and cognitive and memory impairments.
The results suggest that A1-exosomes may be used clinically as
an adjunct to AED therapy after SE. Although an ideal combo of
AEDs would terminate an SE crisis, IN administration of A1-
exosomes shortly after SE termination would help in reducing
the SE-induced neurodegeneration, neuroinflammation, and cogni-
tive and memory impairments, which in turn may considerably re-
duce the predilection of SE to evolve into a chronic epileptic state.
In such situations, IN dispensation of prebanked A1-exosomes
generated from allogenic MSCs from multiple sources may be
used (28–30). There are several advantages of the use of EVs as
opposed to cells. These include their ability to cross the blood–brain
barrier and deliver various therapeutic factors to the brain (25, 26);
amenability for engineering to package specific mRNAs, miRNAs,
and proteins (26, 27); and minimal risk for developing tumors or
causing thrombosis. Future studies will be focused on determining
whether the extent of neuroprotective, antiinflammatory, neuro-
genic, cognitive, and memory-protective effects mediated by A1-
exosomes is adequate to prevent the evolution of SE-induced
initial precipitating injury into a chronic epileptic state.
Materials and Methods
SI Materials andMethods includes descriptions of all materials andmethods used
in the present study. This includes culture conditions, chromatographic isolation
of EVs, timeline of various experiments, induction of SE, IN administration of A1-
exosomes, tracking of PKH-26+ labeled exosomes in the brain, behavioral testing
procedures, immunohistochemistry for neuroinflammation and neuroprotection
analyses, stereological cell-counting methods, and measurement of microglia
with ImageJ software. Human bonemarrow-derivedMSCs were from the Center
for MSC Distribution (medicine.tamhsc.edu/irm/msc-distribution.html), and the
Texas A&M Animal Care and Use Committee approved all animal protocols.
Human bone marrow-derived MSCs were obtained from normal, healthy donors
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after informed consent in accordance with procedures approved by the Scott &
White and Texas A&M Institutional Review Boards.
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